Exhibit 10.7

SECOND AMENDMENT TO LICENSE AGREEMENT

 

This Second Amendment to the License Agreement dated June 22, 2000 is made as of the 10 th day of June, 2002 by and between the University of Florida Research Foundation, Inc. ("UFRF"), a nonstock, nonprofit Florida corporation, and Oragenics, Inc. (formerly OraGen, Inc.) ("Licensee"), a corporation organized and existing under the laws of Florida.

WHEREAS, UFRF and Licensee (collectively "the Parties") entered into a License Agreement covering certain Licensed Patents, made effective June 22, 2000, and first amended on September 15, 2000; and

WHEREAS, the Parties have agreed to amend certain terms of the License Agreement, as amended;

NOW THEREFORE, in consideration of the mutual covenants and agreement set forth below, the Parties hereby amend Appendix A of the License Agreement as follows:

Activity

Completion Date

 

 

Complete pre-clinical studies, including animal
Toxicity and efficacy

July 1, 2003

 

 

Submit IND to the FDA

September 1, 2003

 

 

Complete Phase 1 Clinical Studies

May 1, 2004

 

 

Complete Phase 2 and 3 Clinical Studies

October 1, 2005

 

 

Submit NDA (as new antibiotic with specific claims)

March 1, 2006

 

 

Receive FDA approval to market

May 1, 2007

 

 

First commercial sale

November 1, 2007

 

 


The License Agreement, as amended, except as further amended herein, shall remain in full force and effect and is hereby ratified and confirmed.

IN WITNESS WHEREOF, the Parties hereto have duly executed this Second Amendment to the License Agreement on the dates indicated below.

UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

 

 

BY:

/s/ David L. Day

Date:

June ___, 2002

 

David L. Day
Director, Office of Technology Licensing

 

 

 

ORAGENICS, INC.

 

 

By:

/s/ Mento A. Soponis

Date:

June ___, 2002

 

Mento A. Soponis
President & Chief Executive Officer

 

 

 

 

UFRF Ref:     UF #1712
                      UF #10216

 

-2-